Dr. Richard Murray, prominent pulmonologist, joins Spire Health as Chief Medical Officer
Spire, Inc., a leading innovator in actionable respiratory monitoring, announced today that it has rebranded as Spire Health (www.spirehealth.com). The new name reflects Spire Health’s focus on applying its unique respiratory monitoring technology and passive form factor to the healthcare market. Spire Health has also announced three key healthcare executive appointments. Richard Murray, MD, will serve as the company’s Chief Medical Officer, Phil Golz as the VP of Healthcare Sales and Strategy, and Joanne Hollenbach as the VP of Clinical and Regulatory Affairs.
Dr. Murray brings extensive medical expertise and a background as a pulmonologist to Spire Health. As Chief Medical Officer, he will help guide Spire Health’s remote patient monitoring product development, healthcare partnerships, and clinical trials. Dr. Murray was formerly at Merck & Co. in a variety of senior medical and scientific positions, including Deputy Chief Medical Officer. He currently serves on the board of the Foundation of the American Thoracic Society (FATS) and is Chairman of the Board of the Asthma and Allergy Foundation of America (AAFA).
Dr. Murray expressed his enthusiasm in joining the company, stating that “I strongly believe that Spire Health’s respiratory technology and form factor will transform the way that Chronic Obstructive Pulmonary Disease (COPD) and other respiratory conditions are monitored and managed. Health Tag is one of the most exciting health technologies I’ve seen that provides new insights into what respiratory patients are actually experiencing.”
As VP of Healthcare Sales and Strategy, Mr. Golz will drive Spire Health’s commercial strategy and establish healthcare partnerships. Mr. Golz spent 10 years at GlaxoSmithKline, where he led global digital strategy and innovation, and more recently spent 3 years as Executive Vice President leading commercial development at HealthUnlocked.
Ms. Hollenbach will oversee the expansion and growth of Spire Health’s clinical and regulatory operations, as well as its quality infrastructure and processes, and ensure alignment with FDA guidelines. She brings more than 25+ years of experience in clinical operations, including her role as the US Chief Operating Officer for Cmed Inc. Most recently, she was the VP of Global Clinical Development at WCCT Global, where she led clinical trials for multiple pharmaceutical, biotech, and medical device companies.
Spire Health will focus on remote patient monitoring for chronic conditions, particularly COPD, asthma, and congestive heart failure. The Centers for Medicare and Medicaid (CMS) introduced three new remote patient monitoring reimbursement codes for 2019, a change reflective of the market trend towards remote care. The changes from CMS support Spire Health’s intent to work with providers and payers in deploying its technology and delivering cost effective, high-quality care. Spire Health’s clothing-adhered Health Tag technology is an ideal solution due to its high patient adherence and robust respiratory data.
Spire Health’s remote patient monitoring solutions are based on novel respiratory sensing technology that has been developed over the past five years. The company has introduced two successful consumer-oriented products, Spire Stone and Spire Health Tag, selling over 150,000 units. By initially focusing on the consumer market, the company has been able to optimize its product experience and train machine learning models on billions of respiratory data points. This has enabled Spire Health to demonstrate the long-term user adherence and clinical-grade accuracy that is essential to driving healthcare outcomes.